Invention Grant
- Patent Title: Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
-
Application No.: US16929342Application Date: 2020-07-15
-
Publication No.: US11542309B2Publication Date: 2023-01-03
- Inventor: Ronald M. Evans , Michael Downes , Annette Atkins , Sihao Liu , Ruth T. Yu
- Applicant: Salk Institute for Biological Studies
- Applicant Address: US CA La Jolla
- Assignee: Salk Institute for Biological Studies
- Current Assignee: Salk Institute for Biological Studies
- Current Assignee Address: US CA La Jolla
- Agency: Klarquist Sparkman, LLP
- Main IPC: C07K14/50
- IPC: C07K14/50 ; A61P3/10 ; A61K9/00 ; A61K45/06 ; A61K38/00
Abstract:
The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided.
Public/Granted literature
Information query
